SCHEMBL3543262

SCHEMBL3543262

C=CCOc1c(CC=C)cc(C(=O)OC)cc1OC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.50
SMN1; SMN2 Q16637 5/20 0.50
ALDH1A1 P00352 5/20 0.50
HPGD P15428 3/20 0.50
NPC1 O15118 3/20 0.50
RAB9A P51151 3/20 0.50
HSP90AA1 P07900 2/20 0.50
HTT P42858 1/20 0.50
TSHR P16473 1/20 0.46
PTPN1 P18031 1/20 0.44
HSD17B10 Q99714 1/20 0.42
MAPT P10636 3/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
POLB P06746 2/20 0.42
MEN1 O00255 1/20 0.42
GAA P10253 1/20 0.42
CASP6 P55212 1/20 0.42
KMT2A Q03164 1/20 0.42
MCL1 Q07820 1/20 0.42
GPR55 Q9Y2T6 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3543111 0.89 TSHR (0.47) KDM4EALDH1A1TSHRPTPN1MAPT
SCHEMBL3547387 0.88 KDM4E (0.57) KDM4ESMN1; SMN2ALDH1A1HPGDNPC1
SCHEMBL27317693 0.85 KDM4E (0.53) KDM4ESMN1; SMN2ALDH1A1TSHRMEN1
SCHEMBL14211106 0.83 KDM4E (0.50) KDM4ESMN1; SMN2ALDH1A1HPGDNPC1
SCHEMBL3542435 0.82 KDM4E (0.44) KDM4ESMN1; SMN2ALDH1A1HPGDNPC1
SCHEMBL3548293 0.82 POLB (0.48) KDM4EALDH1A1HPGDPTPN1MAPT
SCHEMBL3544993 0.80 KDM4E (0.51) KDM4EALDH1A1TSHRPTPN1MAPT
SCHEMBL23776767 0.79 KDM4E (0.53) KDM4ESMN1; SMN2ALDH1A1HPGDNPC1
SCHEMBL13400919 0.78 LMNA (0.55) KDM4ESMN1; SMN2ALDH1A1HPGDNPC1
SCHEMBL14204739 0.78 CYP3A4 (0.46) KDM4ESMN1; SMN2ALDH1A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691843-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2010-04-06 US disclosed
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity VICURON HOLDINGS LLC 2008-03-06 US disclosed
EP-1539744-A4 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARM INC (US) 2007-06-06 EP disclosed
EP-1539744-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2005-06-15 EP disclosed
WO-2004007444-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS, INC. (US) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity AMDHD2, OGA, ENGASE KDM4E 2323/4885SMN1; SMN2 3846/4885ALDH1A1 2309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.